Abstract
INTRODUCTION
Rheumatoid arthritis (RA) is a severe autoimmune disease. Leflunomide (LEF) is commonly used for the immunosuppressive treatment of RA. 1 It can inhibit dihydroorotate dehydrogenase activity and influences the pyrimidine nucleotide synthesis pathway. It also inhibits the activity of tyrosine kinases preventing signal transduction and T cell activation. Furthermore, leflunomide's metabolites are thought to affect the production of metalloproteinases by synovial fibroblasts and may inhibit the synthesis of nitric oxide (NO). 2 Xinfeng capsule (XFC) is a Chinese patent medicine that has been widely used in the clinical treatment of RA. It consists of Huangqi (Radix Astragali Mongolici), Yiyiren (Semen Coicis), Wugong (Scolopendra) and Leigongteng (Radix et Rhizoma Tripterygii), which are components based on the theory of monarch, which means basic principles of compatibility of prescriptions. XFC has the effect of supplementing Qi, strengthening the spleen and promoting blood circulation. 3 Huangqi (Radix Astragali Mongolici) and Yiyiren (Semen Coicis) are sovereign drugs, which play a major role, and can enhance immunity, are anti-inflammatory and protective of gastric mucosa. 4, 5 Wugong (Scolopendra) and Leigongteng (Radix et Rhizoma Tripterygii) are minister drugs, which play a secondary role, and are anti-inflammatory and can regulate immunity and microcirculation. 4, 5 Existing studies show that XFC can effectively regulate the serum levels of cytokines in RA patients and Adjuvant arthritis rat ( AA rats) ; these cytokines include interleukin (IL)-1b tumor necrosis factor (TNF)-a, IL-4 and IL-10. 6, 7 The high-performance thin-layer chromatography (HPTLC) fingerprint chromatographic for the evaluation of XFC is shown in preliminary studies. 8 Fingerprint is based on the research of chemical components of Chinese medicine, which is mainly used in the evaluation of authenticity, quality and stability. In several clinical trials, the progression of RA was closely related to the dysfunction of B lymphocytes. [9] [10] [11] B cell-activating factor (BAFF) is a member of the TNF super family, which plays an important role in the regulation of both the innate and adaptive immune responses. 12 Studies have shown that serum BAFF levels in patients with active RA were significantly higher than those in normal subjects. Therefore, we analyzed the levels of BAFF/BAFF-R in 45 patients with RA, along with the levels of immunoglobulin (Ig) G (subtypes 1-4), IgA, and IgM, following treatment with XFC.
MATERIALS AND METHODS

Study population
Eligible patients were between 18 and 65 years of age and had been diagnosed with active RA based on the American Rheumatism Association (ACR) 1987 revised criteria. 13 They were classified into functional class Ⅰ or Ⅲ according to the Modified Disease Activity Score (3 variables; DAS28-3) 14 promulgated by the European Union of anti-rheumatism. The disease activity of RA patients and classification was judged by DAS28-3. Patients were excluded if they were taking corticosteroids (≤ 15 mg prednisone or equivalent) ≥ 4 weeks before entering the trial, if they had high disease activity (DAS28-3 scores > 5.1) or they were diagnosed as suffering any other chronic inflammatory disease or connective tissue disease, such as Sjögren syndrome, or systemic lupus erythematosus.. Additionally, patients were excluded from the study if they suffered severe disease of the cardiovascular system, brain, lung, liver, kidney, gastrointestinal system or hematopoietic system, were pregnant or nursing, were a psychiatric patient, possessed a white blood cell (WBC) count ≤ 3. 
Measurement of disease severity
Clinical assessments of disease severity and safety measures were obtained at baseline and at weeks 4, 8, and 12. A standard evaluation of the overall RA severity was used according to the American Rheumatism Association (ACR) recommended in 2002. It contained the following criteria: swollen joint count, tender joint count, Health Assessment Questionnaire (HAQ), C-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR), rest pain intensity assessment and overall condition of patients as measured on a visual analog scale (VAS) ranging from 0 mm (no pain) to 100 mm (severe pain); and the VAS score was integrated by doctors. This was called ACR 20% improvement criteria (ACR20) when the first two criteria reduced by at least 20% and at least three of the remaining criteria improved by 20%. ACR50 and ACR70 represent a clinical disease activity improvement of at least 50% or 70%, respectively. The primary efficacy endpoint was the proportion of patients who had achieved responses according to the proportion of ACR20 at week 12. The secondary efficacy end points were the proportion of patients with ACR50 and ACR70 at week 12. Laboratory parameters included: CRP, ESR, rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP) antibodies, glucose-6-phosphate isomerase (GPI), d-dimer, and routine coagulation examinations. Life quality assessments included: Health assessment questionnaire (HAQ), which used to assess the functional status of patients. The safety assessment included a physical examination of basic vital signs and electrocardiogram (ECG) before the study and at 12-week intervals over the course of the study. Liver and kidney function tests were taken at baseline, and subsequently at 4, 8 and 12 weeks.
Treatment
The experimental group took XFC and an LEF placebo, orally. XFC was taken as three capsules per dose, taken 3 times a day immediately after meals for 3 months; 10 mg of the LEF placebo was taken orally, once a day immediately after a meal, for 3 months. The control group was orally administered LEF and XFC placebo. LEF was taken 10mg each time, once a day immediately after a meal, for 3 months; XFC placebo comprised three capsules, taken 3 times per day immediately after meals, for 3 months. XFC and its placebo were produced by the Preparation Department of the First Affiliated Hospital of Anhui University of Chinese Medicine (Anhui Pharmacists; Certification Z20050062). LEF and its placebo were produced by Fujian Huitian Biological Pharmacy Co., Ltd. (Fujian, China) (drug approval number: H20050175; 10 mg per pill). The participants were followed-up 4 weeks after treatment by telephone.
Trial design
This study was a randomized, controlled, double-blind, double-dummy trial. The central randomization system was used by the Clinical Evaluation Center at the China Academy of Chinese Medical Sciences (CACMS) in Beijing.
Randomization
This research adopted the hierarchical block randomized method. The implementation of the random scheme used the central stochastic system. The statistics personnel at the Clinical Evaluation Center of CACMS used the statistical software PROC PLAN program of SAS 9.1.3 (SAS Institute, Inc., Cary, NC, USA) for randomization. Subjects were randomly divided into four centers and two groups.
Blinding
The patients, researchers and data managers were all blinded throughout this study.
Statistical analysis
The quantitative data were expressed as mean ± standard deviation ( x ± s ) Data were analyzed with SPSS19.0 (SPSS, Chicago, IL, USA) software and Spearman rank test and t tests were performed. Results were deemed statistically significant when P < 0.05.
RESULTS
In this study, 45 patients were randomly assigned to the XFC group (23 cases) or the LEF group (22 cases). After 12 weeks of treatment, 3 cases from the LEF group and 2 cases from the XFC group had left the trial. These participants all left because private reasons. There were no significant differences in demographic characteristics, vital signs, medical history, or diagnosis between the two groups. In the two groups at baseline in the PPS data sets, the patients' overall assessment of arthritis pain, disease activity, physicians' global assessment of disease activity, time of morning stiffness, joint pain, joint swelling, joint function classification, DAS28-3 showed no statistical differences. Thus, we conclude that the two groups were comparable at baseline.
Clinical efficacy
The main efficacy index was ACR20 and the secondary efficacy indices were ACR50 and ACR70: after 12 weeks of treatment, ACR 20% improvement criteria (ACR20) was 85% for the XFC treatment group, compared with 85% for the LEF control group. For the ACR50 criteria, the results were 40% and 70% for the two groups, respectively, with the ACR70 criteria showing 15% and 25%, respectively. There were no statistical differences between the two groups (P > 0.05), showing that XFC has equivalent efficacy to LEF (Table 1) .
Immunoglobulins (IgA, IgG, IgM)
The results showed that the presence of immunoglobulins, IgA, IgG and IgM in the XFC group and the LEF group were elevated, especially IgG titers. (In healthy: IgA 0.7-4.06 g/L, IgG 6.8-14.5 g/L, IgM 0.4-2.5 g/L.) After 12 weeks of treatment, the two groups showed a tendency toward reduced immunoglobulin levels, but no statistical significance was found (P > 0.05) ( Table 2) . cantly reduced in the XFC group compared with the LEF group, after 12 weeks of treatment (P < 0.05, Table 3). This suggests that XFC was able to decrease IgG1 expression, while LEF had a tendency to increase it. After 12 weeks, the expression of BAFF-R in the XFC group was significantly lower than in the LEF group (P < 0.01, Table 3) Correlation between immunoglobulin titer and laboratory index Correlation analysis showed that IgG2 positively correlated with CRP (P < 0.01); IgG3 positively correlated with WBC and CRP (P < 0.01); and IgG4 and C4 positively correlated (P < 0.01). BAFF negatively correlated with LYMPH# (P < 0.01), while BAFF-R and PLT and AGP were positively correlated (P < 0.01, Table 3 Comparison of BAFF/BAFF-R and the IgG subtypes （ x ± s） Notes: LEF group use leflunomide (1 tablets per day) for 1 week till 12 weeks; XFC group use Xinfeng capsule (9 tablets per day) for 1week till 12 weeks.: After 12 weeks treatment, compared with LEF group, BAFF in XFC group is significant lower , a P < 0.05; In Xinfeng Capsule Group, the expression of BAFF-R after 12 weeks treatment is lower than 1 week treatment, b P < 0.05 , and it also lower than which in LEF group, c P < 0.01; After 12 weeks treatment, IgG1 in XFC group is lower than it in LEF group, prevalent disease and results in a huge economic burden to the healthcare system in China because of its long duration, high disability rate and treatment cost. 15 Early initiation of disease-modifying anti-rheumatic drugs prior to the onset of cartilage destruction has been shown to prevent or significantly diminish the extent of joint destruction developed during RA. 16 The aim of this study was to explore the utility of treating RA with XFC and analyzing the level of disease correlates, including IgG subtypes and BAFF/BAFF-R. IgG1, IgG2, IgG3 and IgG4 are the 4 subtypes of IgG according to their heavy chain structure. Each subtype has its own biological characteristics, for example, IgG1 and IgG3 have the greatest ability to activate complement and antibody-dependent cellular toxicity. IgG3 has the shortest half-life, while IgG2 and IgG4 only weakly activate complement and binding to the surface of macrophages. 17 In vivo, IgG is produced by B lymphocytes. B lymphocyte proliferation and antibody production are mediated by BAFF, which has two forms; a membrane bound form and soluble form. Soluble BAFF (sBAFF; aa83-285) has the same biological activity as full length BAFF protein. Studies suggest that sBAFF can enhance the function of B cells, CD4 T cells and NK cells; thus, enhancing the overall immune response. 18 One study confirmed that the over-expression of BAFF is closely related to the pathogenesis of RA. 19 BAFF-R is a positive regulator in the differentiation of B cells. Test results showed that the ACR20, ACR50 and ACR70 in the XFC group at week 4, week 8, and week 12 were not significantly different from those of the LEF group (P > 0.05). This suggests that the ACR20, ACR50, and ACR70 of XFC in other studies are likely comparable. Furthermore, at each treatment time point in this study, the ACR20, ACR50 and ACR70 of the XFC group was not lower than that of the LEF group. Based on previous studies, 20, 21 reference to healthy control group, we found that IgG levels changed before and after treatment. The results showed that IgA, IgG and IgM were increased before XFC treatment, especially IgG (60% and 45% ). IgG subtypes, including IgG1, IgG2, IgG3, IgG4, as well as BAFF and BAFF-R were detected in the blood samples of 40 RA patients. At 12 weeks after treatment, BAFF and IgG1 from patients in the LEF group and XFC group were significantly different (P < 0.05). The results showed that the expression of IgG1 significantly decreased in the XFC group, while it was slightly elevated in the LEF group (P > 0.05). The expression of BAFF-R was significantly decreased in the XFC group after 12 weeks, compared with the LEF group. XFC is based on a traditional Chinese medicine, Jianpi Yiqi Tongluo principle, 22 which means strengthening the spleen and replenishing Qi and dredging collaterals, and is composed of Huangqi (Radix Astragali Mongolici), Yiyiren (Semen Coicis), Wugong (Scolopendra) and Leigongteng (Radix et Rhizoma Tripterygii). Huangqi (Radix Astragali Mongolici) Yiqi Jianpi, Buzhong Gubiao, which means invigorating Qi and strengthening spleen, and invigorating Qi for strengthening superficies, are thought to downregulate inflammatory mediators, such as IL-8, TNF-α, and NO, as well as increase the expression of glucocorticoid receptors on inflammatory cells. 23, 24 These inflammatory mediators could activate immune response. Yiyiren (Semen Coicis) can fortify the spleen and drain dampness, stimulate the circulation of the blood and cause the muscles and joints to relax. Leigongteng (Radix et Rhizoma Tripterygii), which can eliminating wind and dampness, reducing swelling and pain, are thought to decrease the expression of IL-12, TNF-α. 25, 26 It has been found that the levels of IgM, IgA and IgG in patients can be improved after treatment through inhibit immunological response. 27, 28 In this experiment IgA, IgG, and IgM were not significantly improved by XFC treatment; however, a significant decrease in BAFF/ BAFF-R and decreased IgG1 were observed. It is possible that XFC might lower the level of IgG1 by decreasing BAFF/BAFF-R in RA patients, which may regulate humoral immunity. Therefore, for rheumatoid arthritis patients, the Xinfeng capsules can also achieve the anti-inflammatory and analgesic, adjust the immune function. It provide a new choice for rheumatoid arthritis patients.
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